Tradipitant

Overview

Tradipitant has been used in trials studying the treatment and prevention of Eczema, Pruritus, Gastroparesis, Chronic Pruritus, and Atopic Dermatitis, among others.

Background

Tradipitant has been used in trials studying the treatment and prevention of Eczema, Pruritus, Gastroparesis, Chronic Pruritus, and Atopic Dermatitis, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis	2025/02/20	NCT06836557	Phase 3	Recruiting	Vanda Pharmaceuticals
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use	2025/02/03	NCT06804603	Phase 2	Recruiting	Vanda Pharmaceuticals
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness	2023/11/18	NCT06138613	Phase 3	Recruiting	Vanda Pharmaceuticals
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness	2023/06/15	NCT05903924	Phase 3	Completed	Vanda Pharmaceuticals
Tradipitant for Functional Dyspepsia	2022/12/16	NCT05653310	Phase 2	ENROLLING_BY_INVITATION	Xiao Jing (Iris) Wang
Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers	2021/04/19	NCT04849559	Phase 1	Completed	Vanda Pharmaceuticals
Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis	2020/07/17	NCT04474990	N/A	AVAILABLE	Vanda Pharmaceuticals
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness	2020/03/31	NCT04327661	Phase 3	Completed	Vanda Pharmaceuticals
ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection	2020/03/30	NCT04326426	Phase 3	ENROLLING_BY_INVITATION	Vanda Pharmaceuticals
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)	2019/10/28	NCT04140695	Phase 3	Terminated	Vanda Pharmaceuticals

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Vanda Pharmaceuticals Appeals to Supreme Court Over FDA's Fast-Track Denial for Gastroparesis Drug

a month ago

Vanda Pharmaceuticals has petitioned the U.S. Supreme Court to overturn the FDA's decision denying fast-track approval for tradipitant, its gastroparesis treatment candidate.

FDA Budget Cuts Linked to Drug Approval Delays as Small Biotech Faces PDUFA Postponement

2 months ago

Recent government efficiency cuts at the FDA appear to be causing delays in drug approval timelines, with 66% of healthcare professionals surveyed expressing concern about potential PDUFA date postponements.

Vanda Pharmaceuticals Battles FDA Over Gastroparesis Drug Hearing Delays

2 months ago

Vanda Pharmaceuticals has accused FDA officials of unlawfully delaying a hearing on its gastroparesis drug tradipitant, claiming the agency is using recent staff reductions as a false excuse for a six-month postponement.

Vanda Pharmaceuticals Challenges FDA Rejection of Tradipitant for Gastroparesis, Seeks Hearing

7 months ago

The FDA issued a Complete Response Letter for Vanda Pharmaceuticals' tradipitant, a neurokinin-1 receptor antagonist, for treating gastroparesis, citing insufficient evidence of efficacy.

Vanda Pharmaceuticals Reports Revenue Increase and Advances Pipeline in Q3 2024

8 months ago

Vanda Pharmaceuticals reported a 23% increase in Q3 2024 revenues, reaching $47.7 million, driven by sales of Fanapt, HETLIOZ, and PONVORY.

AI-Powered Research

Premium Access